Mereo BioPharma (MREO) Current Leases (2022 - 2026)

Mereo BioPharma (MREO) has reported Current Leases for 5 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Leases rose 71.38% year-over-year to $1.0 million in Q2 2026; TTM through Jun 2026 was $1.0 million, a 71.38% increase from a year earlier, with the FY2025 full-year figure at $202000.0, down 71.43% from the prior year.
• Current Leases was $1.0 million for Q2 2026 at Mereo BioPharma, up from $202000.0 in the prior quarter.
• Over five years, Current Leases peaked at $1.0 million in Q2 2026 and troughed at $202000.0 in Q4 2025.
• A 5-year average of $634272.7 and a median of $662000.0 in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases plunged 71.43% in 2025 and jumped 71.38% in 2026, its largest moves.
• Over 5 years, Current Leases stood at $564000.0 in 2022, then rose by 15.6% to $652000.0 in 2023, then gained by 8.44% to $707000.0 in 2024, then sank by 71.43% to $202000.0 in 2025, then soared by 409.9% to $1.0 million in 2026.
• The last three Current Leases figures came in at $1.0 million (Q2 2026), $202000.0 (Q4 2025), and $397000.0 (Q3 2025), per Business Quant data.